The Efficacy and Safety of Esketamine for the Treatment-Resistant Depression in Older Adults: Comments on TRANSFORM-3 Trial Results

Am J Geriatr Psychiatry. 2020 Feb;28(2):142-144. doi: 10.1016/j.jagp.2019.10.009. Epub 2019 Oct 18.

Authors

Helen Lavretsky¹, Steven P Roose²

Affiliations

¹ Late Life Mood, Stress, and Wellness Program, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA (HL), Los Angeles, CA. Electronic address: hlavrets@ucla.edu.
² College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute (SPR), New York, NY.

PMID: 31734082
DOI: 10.1016/j.jagp.2019.10.009

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Aged
Antidepressive Agents
Depression
Depressive Disorder, Treatment-Resistant*
Humans
Ketamine
Nasal Sprays*

Substances

Antidepressive Agents
Nasal Sprays
Esketamine
Ketamine